Once monthly dose of Actonel approved for postmenopausal osteoporosis
Great news for women who take Actonel for postmenopausal osteoporosis: the FDA approved a new once-a-month dose of Actonel.
Here is the press release:
CINCINNATI and BRIDGEWATER, N.J., April 24 /PRNewswire-FirstCall/ — The U.S. Food and Drug Administration (FDA) approved a new once-a-month dose (150 mg) of Actonel(R) (risedronate sodium) tablets for the treatment and prevention of postmenopausal osteoporosis. Actonel is approved to reduce the risk of fractures in postmenopausal women with osteoporosis.
The FDA approval of the once-a-month dose is based on a study comparing Actonel 150 mg once monthly to Actonel 5 mg daily. Similar increases in bone mineral density (BMD) were seen among patients taking either once-a-month or daily dosing regimens.
Over fifty-five million prescriptions of Actonel have been filled in the U.S. alone since its approval for osteoporosis in 2000. Those who want to learn more about postmenopausal osteoporosis and treatment with Actonel should visit: http://www.Actonel.com.
~~~~~~~
Technorati Tags: osteoporosis,actonel,once a month actonel,risedronate sodium,fractures,postmenopausal osteoporosis,risk of fractures,bone mineral density
Related Stories
POSTED IN: FDA Announcements, News, Ortho (bones, muscles, feet, etc) & osteoporosis, Press releases/Recalls/Warnings
0 opinions for Once monthly dose of Actonel approved for postmenopausal osteoporosis
No one has left a comment yet. You know what this means, right? You could be first!
Have an opinion? Leave a comment: